The two organizations launch a generic drug inspection initiative to support drug approvals.
John Beale, a former senior policy advisor in the agency's Office of Air and Radiation, had pleaded guilty to stealing government money. He has agreed to pay about $890,000 in restitution and about $500,000 to DOJ in criminal forfeiture.
A proposed rule from the agency offers two options: driving with a stable vision condition for at least a year or no specific amount of CMV driving experience required.
The proposal comes in the wake of the Chevron 2012 pipe rupture and fire in the Bay Area.
The study, published in the Journal of Food Protection, points to a lack of safe procedures for raw ground beef and leafy greens in many restaurants.
On Monday, the Federal Railroad Administration began a 60-day rail safety assessment on Metro-North operations.
The FDA proposed a new rule designed to determine both the safety and effectiveness of antibacterial hand soap and body washes.
Inga Beale, currently group chief executive of Canopius, will join Lloyd's in January 2014, the insurance market's chairman announced Dec. 16.
"In Jeh, our dedicated homeland security professionals will have a strong leader with a deep understanding of the threats we face and a proven ability to work across agencies and complex organizations to keep America secure," President Obama said in a White House statement.
Lucian Deacon is based in Denver and will manage the division's public outreach efforts.
The organizations sign a memorandum of understanding to promote global workplace safety efforts.
OSHA cites The Gilman Brothers Co. for over $105,000 in proposed safety violation fines.
The bus companies are shut down for various safety violations.
The “National Survey of Speeding Attitudes and Behaviors” finds nearly half of all drivers speed, among other conclusions.
The safety group has determined that at current levels, aspartame is safe to consume.
The agency is issuing a final guidance document that explains how animal pharmaceutical companies can work with it to voluntarily remove growth enhancement and feed efficiency indications from the approved uses of their medically important antimicrobial drug products.
The drug, which is currently the industry’s best hope for treating Alzheimer’s, moves to big trials.